Pfizer has announced details of what it will look like following the merger with Wyeth, saying that it aims to keep most key Wyeth execs as heads of a new BioTherapeutics Research Group. The small-molecule group will be labelled, creatively, the PharmaTherapeutics Research Group, and will be run by Martin Mackay, who now oversees PGRD. Here's the official release with more.
--PWT
Latest from Home
Latest from Home